A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2001
11/22/2001	WO2001087328A2 Interleukin-1 inhibitors in the treatment of diseases
11/22/2001	WO2001087326A1 Use of an enterobacterium ompa protein as antimicrobial agent
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087289A2 Propofol for treatment of sepsis
11/22/2001	WO2001087286A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087267A1 Protein matrix materials, devices and methods of making and using thereof
11/22/2001	WO2001087234A2 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/22/2001	WO2001087229A2 Treating infections
11/22/2001	WO2001041534A3 Pseudomycin phosphate prodrugs
11/22/2001	WO2001037862A3 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
11/22/2001	WO2001036462A3 Protein c derivatives
11/22/2001	WO2001035991A3 Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
11/22/2001	WO2001034185A3 Induction of mucosal immunity by vaccination via the skin route
11/22/2001	WO2001034119A3 Inhibitors of crystallization in a solid dispersion
11/22/2001	WO2001032691A8 Hcv ns3 protease inhibitors
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001030752A3 Indole compounds for treating bacterial infections
11/22/2001	WO2001029050A3 Condensed pyrrole derivatives as neuraminidase inhibitors
11/22/2001	WO2001027146A3 Chemokine receptor
11/22/2001	WO2001025239A3 Oxazinoquinolones useful for the treatment of viral infections
11/22/2001	WO2001025227A3 Quinolyl propyl piperidine derivatives and their use as antibacterial agents
11/22/2001	WO2001023597A9 Cell lines and constructs useful in production of e1-deleted adenoviruses in absence of replication competent adenovirus
11/22/2001	WO2001019993A3 Virulence genes of m. marinum and m. tuberculosis
11/22/2001	WO2001019385A3 The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	WO2001007637B1 Conditionally controlled, attenuated hiv vaccine
11/22/2001	WO2001000242A3 Polycation-based bioconjugates
11/22/2001	WO2000010600A9 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
11/22/2001	US20010044547 From l-mannonic-gamma-lactone intermediates; for prophylaxis of HIV/AIDS HIV
11/22/2001	US20010044538 Mitogen-activated protein (MAP) kinase; treating inflammatory diseases; compounds such as 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1H-pyrrolo(3,2-b)pyridine
11/22/2001	US20010044537 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine
11/22/2001	US20010044536 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
11/22/2001	US20010044533 Purification process
11/22/2001	US20010044523 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
11/22/2001	US20010044522 Polypeptides, antibodies against them and nucleic acids encoding them; detecting activated CD4+ T-cells to diagnose a disease or condition of the immune system; screening for immunosuppressants
11/22/2001	US20010044468 Reduced in the body to produce a benzamidine; nontoxic
11/22/2001	US20010044432 Administering estradiol derivative
11/22/2001	US20010044420 Treatment of mammalian cancer
11/22/2001	US20010044416 Administering an antigen and a CD4+ T helper (Th2) cell immunostimulatory nucleic acid mucosally or dermally to produce an antigen specific immune response; treating autoimmune diseases, cancer, infections
11/22/2001	US20010044120 Useful for the prevention or treatment of peptic ulcers in humans or mammals.
11/22/2001	US20010043935 Use of polyamino acid derivatives to treat seborrhoea and the associated skin disorders
11/22/2001	US20010043926 Pharmaceutical formulation
11/22/2001	US20010043921 A retroviral vector of a heterologous nucleic acid sequence as well as at least one sequence allowing site-specific integration of the sequence into a non-coding region of a genome; gene therapy of genetic defects; viricides
11/22/2001	US20010043917 Bacteriophage modified by serial passageing or genetic engineering so the modified bacteriophage will remain active in the body for a longer time than the wild-type phage; infections
11/22/2001	US20010043915 Method for administering a cytokine to the central nervous system and the lymphatic system
11/22/2001	DE10021433A1 Antiviral autovaccine, useful e.g. for treating virus-induced tumors or Crohn's disease, obtained by heating tissue containing viruses and antigens in presence of protein crosslinking agent
11/22/2001	DE10020667A1 Neue Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and benzothiazine derivatives and their use in medicaments
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2409813A1 Compositions and methods for treatment of mucosal infections
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409414A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	CA2409225A1 Tricyclic pyrazole derivatives
11/22/2001	CA2409063A1 7-substituted fused ring tetracycline compounds
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2408756A1 Immune potentiating compositions
11/22/2001	CA2408691A1 Compositions and methods for achieving immune suppression
11/22/2001	CA2408530A1 Novel deoxynucleoside kinase enzyme variants
11/22/2001	CA2408408A1 Modulators of tnf- alpha signaling
11/22/2001	CA2407540A1 Propofol for treatment of sepsis
11/22/2001	CA2407469A1 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	CA2407258A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	CA2407099A1 Aralkyl ester soft drugs
11/22/2001	CA2406013A1 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/21/2001	EP1156123A1 Method for detecting a variation of GH1 as indicator of growth hormone dysfunction
11/21/2001	EP1156111A1 Chimeric arterivirus-like particles
11/21/2001	EP1156110A2 G-protein coupled receptor (HFGAN72Y)
11/21/2001	EP1156102A1 Immunodeficiency virus recombinant poxvirus vaccine
11/21/2001	EP1156054A1 Drugs containing phosphoric acid derivatives as the active ingredient
11/21/2001	EP1156040A1 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
11/21/2001	EP1155700A2 Lymphocyte chemoattractant factor and uses thereof
11/21/2001	EP1155695A1 1,3 oxathiolane nucleoside analogues
11/21/2001	EP1155119A1 Bhv-1 gene-deleted virus vaccine
11/21/2001	EP1155037A1 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists therof, and their therapeutic uses
11/21/2001	EP1155035A2 Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof
11/21/2001	EP1155018A1 Crystal modification c of 8-cyano-1-cyclopropyl-7- (1s, 6s-2,8- diazabicyclo - 4.3.0] nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic
11/21/2001	EP1155017A1 [1,8] naphthyridine derivatives having antiviral activity
11/21/2001	EP1155000A1 2-aminopyridines containing fused ring substituents
11/21/2001	EP1154997A1 Pharmaceutically active compounds and methods of use thereof
11/21/2001	EP1154988A1 Mevinolin derivatives
11/21/2001	EP1154803A1 Immobilized labeling compounds and methods
11/21/2001	EP1154797A2 Multi-mutant diphtheria toxin vaccines
11/21/2001	EP1154793A1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens
11/21/2001	EP1154791A2 Neisserial vaccine compositions and methods
11/21/2001	EP1154790A2 Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
11/21/2001	EP1154787A2 Synergistic combination for treatment of viral-mediated diseases
11/21/2001	EP1154775A1 Therapeutic aqueous composition containing a hexahydro-5-pyrimidinamine compound and a polyalkoxylated fatty alcohol
11/21/2001	EP1154692A1 A method of controlling fungal pathogens, and agents useful for same
11/21/2001	EP0906326B1 Novel aromatic derivatives substituted by a ribose, their method of preparation and application as medicine
11/21/2001	EP0873340B1 Heterocyclic substituted cyclopentane compounds
11/21/2001	EP0842191B1 Cyclosporin derivatives with anti-hiv activity
11/21/2001	EP0810877B1 Hepatitis b vaccine
11/21/2001	EP0711305B1 Protegrins
11/21/2001	CN1323316A 丙型肝炎三肽抑制剂 Tripeptide inhibitor of hepatitis C
11/21/2001	CN1323314A Inhibitors of caspases
11/21/2001	CN1323310A Photocyclized rapamycins
11/21/2001	CN1323309A Phenyl yanthine derivatives
11/21/2001	CN1323308A New compounds
11/21/2001	CN1323225A Polymer conjugates of interferon beta-1a and their uses
11/21/2001	CN1323223A Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

1 ... 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 ... 1798